Biblio

Author Title Type [ Year

]

Filters: Author is Cho, Seok-Goo [Clear All Filters]

2024

Park S, Bang S-Y, Kwag D, Lee JHyuk, Kim TYoon, Lee J, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, et al. Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1. Bone Marrow Transplant. 2024.

2022

Jeon Y, Lim J-Y, Im K-I, Kim N, Cho S-G. BAFF blockade attenuates acute graft-versus-host disease directly the dual regulation of T- and B-cell homeostasis. Front Immunol. 2022;13:995149.

Kwag D, Cho B-S, Bang S-Y, Lee JHyuk, Min G-J, Park S-S, Park S, Yoon J-H, Lee S-E, Eom K-S, et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 2022;12(12):169.

2021

Cho B-S, Yahng S-A, Min G-J, Park S, Park S-S, Shin S-H, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, et al. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. Transplant Cell Ther. 2021.

2020

Park S, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, Shin S-H, Yoon J-H, Lee S-E, Cho BSik, Eom K-S, et al. Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression. Biol Blood Marrow Transplant. 2020.

Shin S-H, Park S-S, Park S, Jeon Y-W, Yoon J-H, Yahng S-A, Cho B-S, Kim Y-J, Lee S, Kim H-J, et al. Nonmyeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. Eur J Haematol. 2020.

Lee S-E, Min GJune, Park S-S, Park S, Yoon J-H, Shin SHwan, Cho B-S, Eom K-S, Kim Y-J, Lee S, et al. Outcomes of haploidentical stem cell transplantation using total body irradiation (600 cGy) and fludarabine with ATG in adult patients with severe aplastic anemia: A prospective phase II study. Biol Blood Marrow Transplant. 2020.

2019

Lee S-E, Lim J-Y, Bin Ryu D-, Kim TWoo, Park SSoo, Jeon Y-W, Yoon J-H, Cho B-S, Eom K-S, Kim Y-J, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019.

Lee HLim, Jang JWon, Han JWon, Lee SWon, Bae SHyun, Choi JYoung, Han NIk, Yoon SKew, Kim H-J, Lee S, et al. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. Dig Dis Sci. 2019.

Cho B-S, Jeon Y-W, Hahn A-R, Lee T-H, Park S-S, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, Lee S, et al. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. Cancer Med. 2019.

Jeon Y-W, O J-H, Park K-S, Min GJune, Park S-S, Yoon J-H, Eom K-S, Min C-K, Cho S-G. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. Br J Haematol. 2019.

Cho B-S, Min G-J, Park S-S, Shin S-H, Yahng S-A, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, et al. WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates. Biol Blood Marrow Transplant. 2019.

2018

Park S-S, Jeon Y-W, Min GJune, Park S, Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Cho B-S, Eom K-S, et al. Graft-versus-host disease free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018.

2015

Im K-I, Kim N, Lim J-Y, Nam Y-S, Lee E-S, Kim E-J, Kim HJin, Kim SHa, Cho S-G. The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release. J Immunol. 2015.

Kim N, Nam Y-S, Im K-I, Lim J-Y, Lee E-S, Jeon Y-W, Cho S-G. IL-21-expressing mesenchymal stem cells prevent lethal B-cell lymphoma through efficient delivery of IL-21, which redirects the immune system to target the tumor. Stem Cells Dev. 2015.

Sohn D-H, Sohn H-J, Lee H-J, Lee S-D, Kim S, Hyun S-J, Cho H-I, Cho S-G, Lee S-K, Kim T-G. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs. PLoS One. 2015;10(5):e0127899.

Yoon J-H, Kim H-J, Jeon Y-W, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. Genes Chromosomes Cancer. 2015.

Kim N, Jeon Y-W, Nam Y-S, Lim J-Y, Im K-I, Lee E-S, Cho S-G. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. Cytokine. 2015;78:22-26.

2014

Lee S-E, Yoon J-H, Shin S-H, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Lee JWook, Min W-S, et al. Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biomed Res Int. 2014;2014:982504.

2013

Kim N, Cho S-G. Clinical applications of mesenchymal stem cells. Korean J Intern Med. 2013;28(4):387-402.

Min C-K, Lee S-E, Yahng S-A, Cho B-S, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Kim D-W, et al. The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma. Blood Res. 2013;48(3):198-205.

Yoon J-H, Kim H-J, Shin S-H, Yahng S-A, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. Int J Hematol. 2013.